Compare Amphastar Pharmaceuticals Inc (AMPH) vs American States Water Company (AWR) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

American States Water (AWR) trades at $84.51, up 0.78% today, with a bullish technical outlook supported by moving averages and strong momentum indicators. The company reported solid 2025 results with $658M revenue and $130M net income, maintaining a robust 19.66% net margin. Recent news highlights its inclusion in TIME's America's Best Companies 2026 list and a completed $200M equity offering, reinforcing its stable utility model and 71-year dividend growth streak.

AWR offers defensive appeal with reliable dividends and infrastructure investments, but faces execution risks from regulatory approvals and interest rate sensitivity. Analyst consensus is mixed with 20% buy ratings, reflecting cautious optimism amid recent earnings misses. The stock's premium valuation (P/E 24.64) requires sustained growth to justify upside potential.